Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCAR-HL30 in Relapsed/Refractory Hodgkin's Lymphoma and ALCL
NCT06494371Phase 1Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jul 2024
- Primary completion
- May 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LCAR-HL30 in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL), sponsored by Ruijin Hospital. Primary endpoints: Incidence, severity, and type of treatment-emergent adverse events at 4 years, Pharmacokinetics in peripheral blood at 4 years and 2 more. Started Jul 2024; status: recruiting.
02
Drugs
LCAR-HL30
03
Conditions
Hodgkin lymphoma (HL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NCT06494371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06494371.